【摘要】 目的:前瞻性地观察使用重组活化凝血因子Ⅶ(rFⅦa,诺其)改善重症急性胰腺炎病人术中的凝血功能及减少术中出血量的有效性。方法:将南京军区南京总医院自2008年3月至2009年10月收治的40例重症急性胰腺炎实施胰周坏死组织清除引流术的病人随机分为两组,一组为rFⅦa组(研究组),一组为对照组,观察两组病人手术前后的凝血指标[包括凝血酶原时间(PT)、部分凝血活酶时间(APTT)、国际标准化比值(INR)、纤维蛋白原(FIB)]和术中出血量。结果:研究组与对照组的PT、INR、术中出血量有显著差异(P<0.001),而APTT、FIB两组间差异无统计学意义(P>0.05)。结论:rFⅦa能改善病人的外源性凝血功能,减少手术中的出血量。更多还原

【Abstract】 Objective To observe the validity of recombinant activated coagulation factor Ⅶ (rFⅦa, NovoSeven) in improving coagulation dysfunction and reducing blood loss during operations on severe acute pancreatitis patients. Methods From March 2008 to October 2009, a total of 40 patients were admitted to Nanjing Military Hospital, and submitted to operations of debridement and drainage of peripancreatic necrotic tissue. The patients were divided at random into 2 groups, the rFⅦa treatment group (test group) and the control group. The perioperative coagulation indicators (including PT, APTT, INR, FIB) and bleeding volume during the operation were compared between these 2 groups. Results There were significant differences in PT, INR and bleeding volume between the test group and the control group (P<0.001). No differences in APTT and FIB were observed between these 2 groups (P>0.05). Conclusion rFⅦa can improve the extrinsic coagulation cascade of SAP patients, and reduce the blood loss during the operation.更多还原